These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma. Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699 [TBL] [Abstract][Full Text] [Related]
4. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. Allouchery M; Lombard T; Martin M; Rouby F; Sassier M; Bertin C; Atzenhoffer M; Miremont-Salame G; Perault-Pochat MC; Puyade M; J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33428586 [TBL] [Abstract][Full Text] [Related]
5. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors. Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774 [TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis. Zhao Q; Zhang J; Xu L; Yang H; Liang N; Zhang L; Zhang F; Zhang X Front Immunol; 2021; 12():730320. PubMed ID: 34646270 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature. Reynolds KL; Guidon AC Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825 [TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival. Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637 [TBL] [Abstract][Full Text] [Related]
16. The Inconsistent and Inadequate Reporting Of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitors: A Systematic Review of Randomized Controlled Clinical Trials. Xie T; Zhang Z; Qi C; Lu M; Zhang X; Li J; Shen L; Peng Z Oncologist; 2021 Dec; 26(12):e2239-e2246. PubMed ID: 34396642 [TBL] [Abstract][Full Text] [Related]
17. Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. Melia A; Fockens E; Sfumato P; Zemmour C; Madroszyk A; Lafforgue P; Pham T Joint Bone Spine; 2023 Jan; 90(1):105457. PubMed ID: 36116771 [TBL] [Abstract][Full Text] [Related]
18. The clinical utility of comprehensive measurement of autoimmune disease-related antibodies in patients with advanced solid tumors receiving immune checkpoint inhibitors: a retrospective study. Izawa N; Shiokawa H; Onuki R; Hamaji K; Morikawa K; Saji H; Ohashi H; Kasugai S; Hayakawa N; Ohara T; Sunakawa Y ESMO Open; 2022 Apr; 7(2):100415. PubMed ID: 35247869 [TBL] [Abstract][Full Text] [Related]
19. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162 [TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience. Bhatlapenumarthi V; Patwari A; Harb AJ J Cancer Res Clin Oncol; 2021 Sep; 147(9):2789-2800. PubMed ID: 33774736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]